Mitsubishi Tanabe Pharma, Daiichi Sankyo enters licensing agreement for ALS treatment agent edaravone in Brazil
Posted on18 Sep 2019
Comments0
Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo announced that they have concluded a licensing agreement covering commercialization rights in Brazil for an... Read More
Alexion’s inlicensing deal for Amyloidosis Candidate In Japan
Posted on12 Sep 2019
Comments0
Alexion Pharmaceuticals announced a license agreement with BridgeBio Pharma’s subsidiary Eidos Therapeutics. Per the terms of the deal, Alexion will obtain an... Read More
Calixar licensing agreement with Regeneron
Calixar SAS, a biotechnology company specialized in native membrane protein stabilization, has entered into an exclusive licensing agreement with Regeneron Pharmaceuticals, Inc.... Read More
Sandoz licensing agreement with EirGenix to commercialize trastuzumab biosimilar
Posted on02 May 2019
TagsBiosimilar, biosimilar deals, biosimilar of sandoz, drug licensing, EirGenix, sandoz, trastuzumab
Comments0
Sandoz, a Novartis division and a global leader in biosimilars, has entered into an agreement to commercialize a proposed trastuzumab biosimilar. This... Read More
Novartis licenses lipoprotein-lowering CVD drug AKCEA-APO(a)-LRx
Posted on26 Feb 2019
Comments0
Excited by strong phase II data, Novartis is exercising its option to license Akcea Therapeutics’ AKCEA-APO(a)-LRx, a treatment to reduce the risk... Read More
How much is the ideal royalty payment in pharmaceutical industry?
A royalty payment is made to the legal owner of the property, patent, copyrighted work, or franchise by licensees or franchisees who... Read More
Eyevance Pharmaceuticals Acquires Worldwide Rights to NEXAGON®
Posted on04 Oct 2018
Comments0
Eyevance Pharmaceuticals, a Fort Worth-based pharmaceutical company committed to developing and commercializing innovative and impactful ophthalmic products, announced a worldwide licensing agreement... Read More
Case Study: Novartis Pharma’s global licensing deal to develop & commercialise MOR106
MOR106 is an investigational, fully human, IgG1 monoclonal antibody directed against the target IL-17C that was generated in a collaboration between MorphoSys... Read More
Benitec’s Axovant exclusive rights to gene therapy for OPMD
Axovant Sciences announced that it has licensed exclusive global rights to an investigational Silence-and-Replace gene therapy program from Benitec Biopharma for the... Read More
Deal Insight: Daiichi Sankyo, DarwinHealth R&D agreement
Daiichi Sankyo Company, Limited and DarwinHealth announced they have entered into a research agreement providing Daiichi Sankyo with exclusive access to DarwinHealth’s... Read More